InsiderSignal.AI

InsiderSignal.ai

PASG - Passage Bio, Inc.

Insider Purchase by Lynx1 Capital Management LP (10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Lynx1 Capital Management LP, serving as 10% owner at Passage Bio, Inc. (PASG), purchased 32,008 shares at $6.99 per share, for a total transaction value of $223,735.00. Following this transaction, Lynx1 Capital Management LP now holds 1,215,725 shares of PASG.

This purchase represents a 3.00% increase in Lynx1 Capital Management LP's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, September 11, 2025 and publicly disclosed via SEC Form 4 filing on Monday, September 15, 2025, 4 days after the trade was made.

Passage Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Lynx1 Capital Management LP

Lynx1 Capital Management LP

10%

Lynx1 Capital Management LP is a Puerto Rico-based hedge fund manager founded in 2020, specializing in long-biased equity investments in U.S. biotechnology and life sciences companies. Headquartered in Dorado, the firm employs a concentrated, data-driven strategy focused on early-stage and innovative healthcare businesses, leveraging in-depth fundamental analysis and sector expertise to identify high-growth opportunities. Led by founder and Managing Partner Weston Nichols, who brings a Ph.D. in Neuroscience from Caltech and prior experience at Perceptive Advisors, Balyasny Asset Management, and SunTrust Robinson Humphrey, Lynx1 emphasizes long-term value creation with a scientific foundation. The firm manages approximately $346 million in assets under management as of its latest Q2 2025 13F filing, with top holdings including Merus N.V. (23.84%), GH Research PLC (23.76%), and Stoke Therapeutics Inc. (17.72%). Lynx1 operates through vehicles like Lynx1 Master Fund LP and serves institutional and high-net-worth clients with a small, specialized team. Notably, it has emerged as a major shareholder in TScan Therapeutics, Inc. (NASDAQ: TCRX), recently acquiring over 10% ownership through multiple transactions, including significant purchases in December 2025 and a prior $30 million investment agreement via pre-funded warrants.

View full insider profile →

Trade Price

$6.99

Quantity

32,008

Total Value

$223,735.00

Shares Owned

1,215,725

Trade Date

Thursday, September 11, 2025

164 days ago

SEC Filing Date

Monday, September 15, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Passage Bio, Inc.

Company Overview

No company information available
View news mentioning PASG

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/350620

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime